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Abstract
Adrenocortical autoantibodies (ACA), present in 60-80% of patients
with idiopathic Addison’s disease, are conventionally detected by
indirect immunofluorescence (IIF) on frozen sections of adrenal
glands. The large-scale use of IIF is limited in part by the need for a
fluorescence microscope and the fact that histological sections can-
not be stored for long periods of time. To circumvent these restric-
tions we developed a novel peroxidase-labelled protein A (PLPA)
technique for the detection of ACA in patients with Addison’s dis-
ease and compared the results with those obtained with the classical
IIF assay. We studied serum samples from 90 healthy control subjects
and 22 patients with Addison’s disease, who had been clinically
classified into two groups: idiopathic (N = 13) and granulomatous (N
= 9). ACA-PLPA were detected in 10/22 (45%) patients: 9/13 (69%)
with the idiopathic form and 1/9 (11%) with the granulomatous form,
whereas ACA-IIF were detected in 11/22 patients (50%): 10/13
(77%) with the idiopathic form and 1/9 (11%) with the granuloma-
tous form. Twelve of the 13 idiopathic addisonians (92%) were
positive for either ACA-PLPA or ACA-IIF, but only 7 were positive
by both methods. In contrast, none of 90 healthy subjects was found
to be positive for ACA. Thus, our study shows that the PLPA-based
technique is useful, has technical advantages over the IIF method (by
not requiring the use of a fluorescence microscope and by permitting
section storage for long periods of time). However, since it is only
60% concordant with the ACA-IIF method, it should be considered
complementary instead of an alternative method to IIF for the detec-
tion of ACA in human sera.
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Introduction
Addison’s disease (AD) results from de-
struction of corticosteroid-producing cells
(1). In Western countries, autoimmune
adrenalitis accounts for approximately 65 to
90% of the cases of primary adrenocortical
insufficiency (2,3).
The presence of circulating adrenal cor-
tex autoantibodies (ACA) is the major marker
of autoimmune AD, being typically found in
60 to 80% of patients with idiopathic AD (2-
6). Conventionally, ACA are detected by
indirect immunofluorescence (IIF) on fro-
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males; median age, 54 years; range, 34-85
years; average disease duration of 5 years,
range 0.1-38 years), followed since 1988 in
the Division of Endocrinology at the Federal
University of São Paulo. Diagnosis of pri-
mary adrenocortical insufficiency was made
based on both clinical findings and the re-
sults of an acute ACTH stimulation test, in
which 60-min cortisol responses were blunted
to 2.2 ± 0.4 µg/dl (range 0.4-5.5 µg/dl, nor-
mal: >18 µg/dl) (24). All patients were al-
ready receiving steroid replacement therapy
at the time of the present study.
The patients were investigated for all
possible causes of AD, especially infectious
or autoimmune adrenalitis. Diagnosis of post-
tuberculosis or post-paracoccidioidomyco-
sis AD was based on history, PPD tests,
presence of antibodies against Paracoccid-
ioidis brasiliensis, and on demonstration of
adrenal calcification by computerized to-
mography (CT). Data concerning the pres-
ence of other autoimmune diseases and anti-
islet cell and anti-microsomal thyroid anti-
bodies were also analyzed.
Prior to the evaluation of ACA, patients
were assigned to two groups: “idiopathic”
and “granulomatous”, according to the most
probable etiology of the primary adrenocor-
tical insufficiency. Patients with adrenal in-
sufficiency due to surgical removal of the
adrenal glands, or with metastatic or hemor-
rhagic destruction were excluded from the
study.
The “idiopathic” group consisted of 13
patients, none of whom presented any evi-
dence of granulomatous disease. A total of
8/13 (62%) patients had one or more autoim-
mune-associated endocrine diseases and/or
were positive for anti-microsomal thyroid
antibodies (APS type II). The remaining 5
(38%) idiopathic patients had AD alone.
None of them were positive for anti-islet cell
antibodies, and in 10, CT of the adrenal
glands showed a volume reduction sugges-
tive of atrophy (Table 1).
The “granulomatous” group consisted of
zen sections of adrenal glands (7,8) and their
presence in healthy subjects can permit the
identification of pre-clinical cases (9-11).
ACA are predominantly IgGs directed
against antigens originating from the cyto-
plasm (6,12,13) of the adrenal cortex cells,
although the existence of surface cell auto-
antigens (14,15) cannot be excluded. Re-
cently, the steroid-synthesizing enzyme 21-
hydroxylase (P450c21) was identified as the
major adrenal autoantigen in isolated AD
and in autoimmune polyendocrine syndrome
type II (APS II) (16,17). In addition, other
P450 cytochromes (such as side-chain cleav-
age enzyme, P450scc, and steroid 17α-hy-
droxylase, P450c17) can trigger an autoim-
mune response in APS type I (APS I) and in
AD with associated premature ovarian fail-
ure (18-20).
A higher prevalence of ACA has been
observed in patients with short disease dura-
tion (4,6) or in APS (21,22). ACA titers can
fluctuate and a progressive decrease is ob-
served after the onset of clinical disease
(23).
The results of the classical IIF technique
depend on the quality of the adrenal cortex
tissue used, and the large-scale use of this
method is limited in part by the need for a
fluorescence microscope and the fact that
histological sections cannot be stored for
long periods of time. Therefore, the develop-
ment of new assays for the detection of
adrenal autoantibodies in human serum is
warranted.
In this study we developed a novel per-
oxidase-labelled protein A (PLPA) technique
for detection of ACA in patients with AD
and compared the results with those ob-
tained with the classical IIF assay.
Material and Methods
Subjects and sera
We analyzed serum samples from 22 pa-
tients with confirmed AD (12 females/10
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9 patients with calcified adrenals on CT
scanning, whose adrenocortical insufficiency
was due to either tuberculosis (N = 4) or
paracoccidioidomycosis (N = 2). Although
none of the patients presented antibodies
against Paracoccidioides brasiliensis, two
of them (AZ and LR, Table 1) had been
treated for paracoccidioidomycosis several
years before the study. In three patients, the
etiology of AD was attributable to a granulo-
matous disease only on the basis of the pres-
ence of adrenal calcification on CT. Among
these patients, one had vitiligo and two were
positive for anti-microsomal thyroid anti-
bodies (Table 1).
Serum samples from 90 healthy control
subjects (57 males/33 females; median age
of 28 years, range 19-81) were also studied.
Written informed consent was obtained
from all subjects after the study protocol had
been approved by the Ethics Committee on
Human Research of the University Hospital.
Peroxidase-labelled protein A technique
(ACA-PLPA)
Fasting serum samples were collected
from all subjects and stored at -20oC until the
assay was performed. Normal post-mortem
human adrenal glands were obtained from
kidney donors. After careful removal of the
fat, the glands were cut into quarters and
Table 1 - Clinical characteristics of the 22 patients with Addison’s disease.
AID: Autoimmune disease clinically manifested (H: Hashimoto’s thyroiditis; GD: Graves’ disease; POF:
premature ovarian failure; CG: chronic atrophic gastritis; DM: type 1 diabetes mellitus; V: vitiligo); TMA:
thyroid microsomal antibodies; ACA-PLPA: adrenocortical antibodies detected by the peroxidase-labelled
protein A technique; ACA-IIF: adrenocortical antibodies detected by indirect immunofluorescence; NA: not
available.
Patient Sex/age Disease AID TMA Calcification PPD Clinical ACA-PLPA ACA-IIF
(years) duration on adrenal CT classification
(years)
GCS F/54 0.1 H + - - idiopathic + +
MJ M/53 0.1 - - - - idiopathic - +
RMM F/43 1.1 - + - - idiopathic + +
JP F/53 2 H/POF + - - idiopathic - +
MB F/37 3 - - - - idiopathic + +
FAF F/58 3 GD - - - idiopathic + -
AB M/36 4.6 - - - - idiopathic - -
MBC F/40 5 - - - NA idiopathic + +
BL M/49 5 - + - - idiopathic + +
VTC F/85 6.7 - - - - idiopathic - +
ELN F/71 9 H + NA - idiopathic + +
JMR F/68 14 H/POF/CG/DM + - - idiopathic + +
IS F/51 15 H/GD/CG + - - idiopathic + -
LAS M/52 1 - - bilateral - granulomatous - -
AMC F/34 1 - - bilateral +++ granulomatous - -
RAS F/53 4.8 - + right +++ granulomatous - -
AZ M/62 5 - - bilateral - granulomatous - -
LR M/61 11 V + bilateral - granulomatous - -
VS M/69 19 - - bilateral +++ granulomatous - -
AO M/60 22 - - left NA granulomatous + +
APJ M/68 28 - - bilateral +++ granulomatous - -
AC M/79 38 - - left - granulomatous - -
1144
Braz J Med Biol Res 31(9) 1998
R.C. Silva et al.
each fragment was wrapped with a cell pro-
tector (Reichert-Jung, LEICA Instruments,
Heidelberg, Germany) and immediately fro-
zen in liquid nitrogen and stored at -70oC.
Unfixed 5-µm sections were used for the
detection of ACA-PLPA.
Frozen sections of the adrenals were fixed
for 5 min with ketone containing 0.2% H2O2
and then washed with Tris-buffer (10 mM
Tris base, 140 mM NaCl, pH 7.4). One hun-
dred µl undiluted serum was added to the
sections, which were incubated in a moist
chamber at room temperature for 30 min.
After incubation, the sections were washed
three times in Tris-buffer, rinsed and incu-
bated at room temperature for 30 min with
100 µl of PLPA (Boehringer-Mannheim
Corp. Biochemical Products, Indianapolis,
IN) diluted 1:50 in 1% bovine serum albu-
min (BSA, Sigma Chemical Co., St. Louis,
MO). After an additional wash with Tris-
buffer, the chromogenic reaction was initi-
ated by the addition of diaminobenzidine
tetrachloride (Sigma) (0.5 mg/ml in 50 mM
Tris base, pH 7.6, containing 0.001% H2O2)
for 10 min. The stained sections were washed
with water, dehydrated with alcohol, plated
and observed under the light microscope by
two different investigators. The brown color
indicated the presence of ACA. When posi-
tive, the serum was re-tested in progressive
dilutions and the ACA-PLPA titer was de-
fined as the maximum dilution of serum
giving a positive stain reaction.
Indirect immunofluorescence (ACA-IIF)
ACA were detected by a classical IIF
technique using thin cryostatic sections of
normal bovine adrenal glands as the source
of antigen. The sections were incubated with
50 µl serum diluted 1:5 in phosphate-buffer
(8 mM Na2HPO4, 1 mM KH2PO4, 140 mM
NaCl, and 3 mM KCl, pH 7.4) for 30 min.
After two washes in phosphate-buffer, 50 µl
fluorescein isothiocyanate-conjugated rab-
bit anti-human IgG (Dako A/S, Glostrup,
Denmark) diluted 1:40 in phosphate-buffer
was added to the sections, which were incu-
bated in a moist chamber for 30 min. After
being washed again with phosphate-buffer,
the sections were plated and observed by
two different investigators using an immuno-
fluorescence microscope. If positive, ACA-
IIF titers were determined by testing serial 2-
fold dilutions of the serum until reaching the
end point.
Other assays
Thyroid microsomal antibodies (TMA)
were detected by semiquantitative aggluti-
nation (Sera-Tek microsomal antibody test
kit, Ames, IN; normal <1/100). Islet cell
antibodies (ICA) were detected by the per-
oxidase-labelled protein A technique on sec-
tions of rat frozen pancreas (25,26) (normal
<10 JDF units).
Antibodies against Paracoccidioides bra-
siliensis were detected by immunodiffusion
(27). Delayed cell hypersensitivity to tuber-
culosis (PPD test) was evaluated by the sub-
cutaneous injection of 2 U of tuberculin into
the anterior surface of the forearm.
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Figure 1 - ACA-PLPA and ACA-IIF levels in patients with “idiopathic” and “granulomatous”
AD. The dotted lines represent the upper normal level for each assay.
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Statistical analysis
Differences in frequencies of ACA be-
tween the two patient groups or between AD
patients and control subjects were tested by
the chi-square method or the Fisher exact
test. The relationship between ACA titers
and disease duration was assessed by linear
regression and the relationship between
ACA-PLPA and ACA-IIF titers by the
Spearman rank correlation test. P values less
than 0.05 were considered significant.
Results
Detection of ACA by the PLPA technique
ACA-PLPA were found in 10 of the 22
patients (45%) with AD and in none of 90
control subjects (P<0.0001). When adrenal
sections were treated with a serum positive
for ACA-PLPA, the cytoplasm of all adrenal
cortex cells homogeneously stained brown,
in contrast with the lack of reactivity of the
capsule and medullary cells. Positive sera
for ACA-PLPA were re-tested several times
using different human adrenal tissues and
every time yielded the same results in terms
of positivity and titer. The rate of concor-
dance between the two readers was 100%.
Among the 10 patients found to be posi-
tive for ACA-PLPA, 9 (69%) were from the
“idiopathic” group and only one (11%) from
the “granulomatous” group (P = 0.01) (Fig-
ure 1). Among the 13 patients with “idio-
pathic” AD, ACA-PLPA were detected in 7
(88%) with APS II and in 2 (40%) with AD
alone.
No significant correlation was found be-
tween the presence or titer of ACA-PLPA
and the duration of primary adrenocortical
insufficiency.
Detection of ACA by the IIF
ACA-IIF were detected in 11 of the 22
patients (50%) with AD and in none of 90
control subjects (P<0.0001).
Among the 11 patients positive for ACA-
IIF, 10 (77%) were from the “idiopathic”
group and only one (11%) from the “granu-
lomatous” group (P = 0.008) (Figure 1).
Among the 13 patients with “idiopathic”
AD, ACA-IIF were detected in 6 (75%) with
APS II and in 4 (80%) with isolated AD.
No significant correlation was found be-
tween the presence or titers of ACA-IIF and
the duration of AD.
Comparison between ACA-PLPA and ACA-IIF
A significant and positive correlation was
observed between ACA-PLPA and ACA-
IIF titers (r2 = 0.70, P<0.01) (Figure 2).
Twelve of the 13 patients (92%) with idio-
pathic AD were positive for either ACA-
PLPA or ACA-IIF, but only 7 (54%) tested
positive for both methods.
Discussion
Detection of circulating ACA is critical
for a correct diagnosis of autoimmune AD.
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Figure 2 - Correlation between ACA-PLPA and ACA-IIF titers in ACA-positive patients (r2 =
0.70; P<0.01). The dotted lines represent the upper normal level for each assay.
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Accordingly, we have developed a novel
peroxidase-labelled protein A (PLPA) tech-
nique for testing ACA in human serum, which
demonstrated diagnostic sensitivity and
specificity similar to that of the classical
immunofluorescence (IIF) assay.
The large-scale use of the IIF assay to
diagnose autoimmune AD depends on the
availability of a special IF microscope and
is limited by the difficulty to distinguish
between antibody-negative and low-level
antibody-positive samples. In addition, his-
tological sections for IIF cannot be stored
for long periods of time. As with the IIF
assay, results of the PLPA-based technique
are somehow subjective, but the possibility
to use a routine light microscope and to
store the sections for long periods of time
makes this assay preferable for those cen-
ters where more complex methods are not
available. The fact that a PLPA-based tech-
nique for anti-islet cell antibodies proved to
have high diagnostic sensitivity and speci-
ficity for IDDM (25,26) is further evidence
that this type of assay can be useful for
clinical diagnosis of endocrine autoimmune
diseases.
Our PLPA technique permitted the de-
tection of ACA in the sera of 45% patients
with primary adrenocortical insufficiency,
regardless of preliminary suspected etiology
and disease duration. Among patients with
clinically “idiopathic” AD, ACA were de-
tected in 69% of cases, as compared to 77%
of cases using the classical IIF assay. The
diagnostic sensitivity of the PLPA technique
for autoimmune AD was not statistically
different from that of the IIF assay. The
frequency of ACA observed in “idiopathic”
AD patients was similar to that found in
previous studies in other countries (2-6).
The presence of adrenal calcification on
CT scanning is considered an exclusion cri-
terion for autoimmune adrenalitis (28,29).
However, in our study, ACA were found in
the serum of one patient whose adrenal gland
was calcified. The presence of ACA in pa-
tients with granulomatous adrenalitis has
been reported before (5,8), but since it is
very unusual (2,6) the possibility of a false
positive result cannot be excluded. Reasons
for false positivity include the presence of
background staining, nonspecific binding and
poor quality of the adrenal cortex tissue. It
seems unlikely that the presence of ACA in
the patient with granulomatous AD was the
result of low specificity of our assay, since
the IIF technique was also positive for ACA
in that patient; in addition, none of 90 con-
trol subjects was found to be positive for
ACA using either IIF or PLPA. The presence
of ACA in this patient may rather have been
due to the presentation to the immune sys-
tem of some adrenal autoantigen resulting
from the inflammatory destruction of the
adrenal cortex and subsequent autoantibody
production in a genetically predisposed sub-
ject. Conversely, one cannot rule out the
possibility that a granulomatous adrenalitis
supervened in a patient with an already on-
going autoimmune process.
Several studies found the prevalence of
ACA to be dependent on the duration of AD.
Wuepper et al. (4) found ACA in 89% of
patients with autoimmune AD within two
years of clinical diagnosis, as compared to
only 50% of patients with two or more years
of disease duration. Nerup (6) also reported
a higher frequency of ACA in the serum of
patients with less than five years of disease
duration (83 vs 58% for five years or more).
In a recent study of Italian AD patients (30),
ACA were found in 73% of patients with
less than 15 years of disease duration as
compared to only 8% in patients with long-
term disease. In our study, the lack of corre-
lation between ACA and duration of the
disease may have been due to the small size
of our sample.
In contrast to other investigators (21,22),
we were unable to find any significant asso-
ciation between ACA and the presence of
APS II, which can also be explained by the
small sample size.
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Although a significant correlation be-
tween ACA-PLPA and ACA-IIF titers was
observed in our study, the concordance rate
between the two assays in idiopathic AD
was not higher than 60%. The different
sources of adrenal tissue (human and bo-
vine) used in the two assays cannot fully
explain the observed difference since en-
zyme expression is similar in both human
and bovine adrenals (31). On the other hand,
the different binding ability of protein A and
of rabbit antisera for human IgG subclasses
may explain, in part, the discrepancies be-
tween the two assays. The use of antigen-
specific immunoprecipitation assays for au-
toantibodies against P450c21 (32,33) or
P450c17 and P450scc (19) could be instru-
mental in the understanding of the mecha-
nisms responsible for the discordance be-
tween ACA-PLPA and ACA-IIF observed in
some patients with AD. Recently, Colls et al.
(34), using an immunoprecipitation assay,
detected autoantibodies against P450c21
(P450c21-Ab) in 66% of patients with au-
toimmune AD and observed a significant
positive correlation between the immuno-
precipitation results and those obtained with
the IIF. This good agreement between meas-
urements of specific P450c21-Ab and ACA-
IIF provided further evidence that P450c21-
reactive autoantibodies are a major compo-
nent of ACA. Moreover, the detection of
P450c21-Ab can accurately identify indi-
viduals at high risk for AD and it is particu-
larly important in the clinical management
of patients with autoimmune endocrinopa-
thies often associated with AD, such as
Hashimoto’s thyroiditis, Graves’ disease,
type 1 diabetes mellitus and premature ova-
rian failure. According to Betterle et al., 21%
of adults (35) and 90% of children (36) with
organ-specific autoimmune diseases (with-
out overt hypoadrenalism) and with positive
ACA-IIF and/or P450c21-Ab developed
clinical AD after a mean latency period of
three years.
In conclusion, this novel PLPA-based
method for the detection of ACA in human
serum showed a diagnostic sensitivity of
69% for autoimmune AD; the technique is
simple, inexpensive and advantageous over
the IIF technique by not requiring the use of
an immunofluorescence microscope and per-
mitting section storage for long periods of
time, but since it is only 60% concordant, it
should be considered complementary instead
of an alternative method to IIF for detecting
ACA in human sera.
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